Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia chromosome-positive CML in first chronic phase

[1]  M. Labopin,et al.  The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). , 1996, Leukemia & lymphoma.

[2]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[3]  H. Einsele,et al.  Immunisations after bone marrow transplantation: results of a European survey and recommendations from the infectious diseases working party of the European Group for Blood and Marrow Transplantation. , 1995, Bone marrow transplantation.

[4]  M. Ladanyi,et al.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. , 1994, The New England journal of medicine.

[5]  H. Minderman,et al.  Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent. , 1993, Seminars in oncology.

[6]  G. Gahrton,et al.  Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. , 1993, Bone marrow transplantation.

[7]  A. Chase,et al.  Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. , 1993, Blood.

[8]  P. Martiat,et al.  Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft‐versus‐host disease and relapse , 1993, British journal of haematology.

[9]  T. Smetsers,et al.  Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Smeets,et al.  Comparison of chromosome studies on PHA-stimulated blood and unstimulated bone marrow cells in recipients of lymphocyte depleted grafts using counterflow centrifugation. , 1993, Bone marrow transplantation.

[11]  T. Lion,et al.  Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia , 1993, The Lancet.

[12]  S. Thibodeau,et al.  Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. , 1992, Bone marrow transplantation.

[13]  A. Barrett,et al.  HLA‐identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome , 1992, British journal of haematology.

[14]  F. Lacombe,et al.  Serial cytogenetic studies in allografted patients with chronic myeloid leukemia. , 1992, Bone marrow transplantation.

[15]  J. D. Thompson,et al.  Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation. , 1992, Blood.

[16]  J. M. Goldman,et al.  Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T‐depleted donor marrow: feasibility of using busulphan alone for re‐conditioning , 1992, British journal of haematology.

[17]  T. Witte,et al.  Intensification of the Conditioning Regimen for Allogeneic Bone Marrow Transplantation in Recipients of T-cell Depleted Grafts by the Addition of Anthracyclines , 1992 .

[18]  A. de Man,et al.  Influence of the conditioning regimen on erythrocyte chimerism, graft-versus-host disease and relapse after allogeneic transplantation with lymphocyte depleted marrow. , 1992, Bone marrow transplantation.

[19]  H. Deeg,et al.  Changing trends in marrow transplantation for aplastic anemia. , 1992, Bone marrow transplantation.

[20]  T. Lion,et al.  Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction. , 1992, Leukemia.

[21]  A. Barrett,et al.  Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. , 1992, Blood.

[22]  D. Ginsburg,et al.  Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. , 1992, Blood.

[23]  J. Ritz,et al.  Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. , 1991, Blood.

[24]  A. Rimm,et al.  T-cell depletion of HLA-identical transplants in leukemia. , 1991, Blood.

[25]  G. Morgan,et al.  Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. , 1991, Blood.

[26]  W. Wilmanns,et al.  Donor Leukocyte Transfusions for Treatment of Recurrent Chronic Myelogenous Leukemia in Marrow Transplant Patients , 1990 .

[27]  P. Martiat,et al.  Detection of residual BCR/ABL transcripts in chronic myeloid leukaemia patients in complete remission using the polymerase chain reaction and nested primers , 1990, British journal of haematology.

[28]  J. Reiffers,et al.  Long-term follow-up after bone marrow transplantation for chronic myelogenous leukemia: factors associated with relapse. , 1990, Bone marrow transplantation.

[29]  J. Raemaekers,et al.  Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation. , 1990, Blood.

[30]  M. Mancini,et al.  Cytogenetic follow-up after allogeneic bone-marrow transplantation for Ph1-positive chronic myelogenous leukemia. , 1990, Bone marrow transplantation.

[31]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[32]  W. Wilmanns,et al.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.

[33]  S. Mackinnon,et al.  Slow evolution of chronic myeloid leukaemia relapsing after BMT with T‐cell depleted donor marrow , 1989, British journal of haematology.

[34]  J. Gabert,et al.  DETECTION OF RESIDUAL bcr/abl TRANSLOCATION BY POLYMERASE CHAIN REACTION IN CHRONIC MYELOID LEUKAEMIA PATIENTS AFTER BONE-MARROW TRANSPLANTATION , 1989, The Lancet.

[35]  W. Lange,et al.  Detection by enzymatic amplification of bcr-abl mRNA in peripheral blood and bone marrow cells of patients with chronic myelogenous leukemia. , 1989, Blood.

[36]  A. Schattenberg,et al.  Prevention of leukemic relapse after transplantation with lymphocyte depleted marrow by intensification of the conditioning regimen with a 6-day continuous infusion of anthracyclines. , 1989, Bone marrow transplantation.

[37]  K. Sullivan,et al.  HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration. , 1988, Blood.

[38]  C. Haanen,et al.  A new multichamber counterflow centrifugation rotor with high-separation capacity and versatile potentials. , 1988, Experimental hematology.

[39]  J. Goldman,et al.  Cytogenetic events after bone marrow transplantation for chronic myeloid leukemia in chronic phase. , 1988, Blood.

[40]  D. Blaise,et al.  IMPACT OF T-CELL DEPLETION ON OUTCOME OF ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR STANDARD-RISK LEUKAEMIAS , 1987, The Lancet.

[41]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[42]  E. Lotzová,et al.  Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. , 1987, Leukemia research.

[43]  R. Elashoff,et al.  Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. , 1986, Annals of internal medicine.

[44]  C. Haanen,et al.  Depletion of donor lymphocytes by counterflow centrifugation successfully prevents acute graft-versus-host disease in matched allogeneic marrow transplantation. , 1986, Blood.

[45]  T. Kipps,et al.  Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen) , 1985, The Journal of experimental medicine.

[46]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[47]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.